1. Home
  2. VIR vs WLFC Comparison

VIR vs WLFC Comparison

Compare VIR & WLFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • WLFC
  • Stock Information
  • Founded
  • VIR 2016
  • WLFC 1985
  • Country
  • VIR United States
  • WLFC United States
  • Employees
  • VIR N/A
  • WLFC N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • WLFC Industrial Specialties
  • Sector
  • VIR Health Care
  • WLFC Consumer Discretionary
  • Exchange
  • VIR Nasdaq
  • WLFC Nasdaq
  • Market Cap
  • VIR 844.9M
  • WLFC 1.2B
  • IPO Year
  • VIR 2019
  • WLFC 1996
  • Fundamental
  • Price
  • VIR $5.41
  • WLFC $138.30
  • Analyst Decision
  • VIR Strong Buy
  • WLFC
  • Analyst Count
  • VIR 7
  • WLFC 0
  • Target Price
  • VIR $33.57
  • WLFC N/A
  • AVG Volume (30 Days)
  • VIR 1.0M
  • WLFC 42.3K
  • Earning Date
  • VIR 05-07-2025
  • WLFC 05-06-2025
  • Dividend Yield
  • VIR N/A
  • WLFC 0.74%
  • EPS Growth
  • VIR N/A
  • WLFC 66.69
  • EPS
  • VIR N/A
  • WLFC 14.50
  • Revenue
  • VIR $20,861,000.00
  • WLFC $594,146,000.00
  • Revenue This Year
  • VIR N/A
  • WLFC $16.35
  • Revenue Next Year
  • VIR $10.65
  • WLFC $10.53
  • P/E Ratio
  • VIR N/A
  • WLFC $9.30
  • Revenue Growth
  • VIR N/A
  • WLFC 35.29
  • 52 Week Low
  • VIR $4.95
  • WLFC $55.31
  • 52 Week High
  • VIR $14.45
  • WLFC $235.43
  • Technical
  • Relative Strength Index (RSI)
  • VIR 35.98
  • WLFC 39.68
  • Support Level
  • VIR $5.83
  • WLFC $124.90
  • Resistance Level
  • VIR $6.29
  • WLFC $158.72
  • Average True Range (ATR)
  • VIR 0.31
  • WLFC 6.80
  • MACD
  • VIR 0.02
  • WLFC 0.23
  • Stochastic Oscillator
  • VIR 28.80
  • WLFC 32.64

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About WLFC Willis Lease Finance Corporation

Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.

Share on Social Networks: